144 related articles for article (PubMed ID: 38483630)
1. Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.
Takenaka M; Tanaka F; Kajiyama K; Manabe T; Yoshimatsu K; Mori M; Kanayama M; Taira A; Kuwata T; Nawata A; Kuroda K
Surg Today; 2024 Mar; ():. PubMed ID: 38483630
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors affecting survival in patients with non-small cell lung cancer treated with salvage surgery after drug therapy: a multi-institutional retrospective study.
Suzuki S; Asakura K; Okui M; Izawa N; Sawafuji M; Sakamaki H; Shigenobu T; Tajima A; Oka N; Masai K; Kaseda K; Hishida T; Yasuda H; Fukunaga K; Asamura H
World J Surg Oncol; 2023 Sep; 21(1):290. PubMed ID: 37715273
[TBL] [Abstract][Full Text] [Related]
3. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
Ohtaki Y; Shimizu K; Suzuki H; Suzuki K; Tsuboi M; Mitsudomi T; Takao M; Murakawa T; Ito H; Yoshimura K; Okada M; Chida M;
Lung Cancer; 2021 Mar; 153():108-116. PubMed ID: 33482408
[TBL] [Abstract][Full Text] [Related]
4. Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer.
Goto E; Hattori A; Fukui M; Matsunaga T; Takamochi K; Suzuki K
Surg Today; 2024 Mar; ():. PubMed ID: 38517532
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.
Chen YY; Lin KH; Kuo YS; Tsai YM; Huang HK; Huang TW
World J Surg Oncol; 2023 Oct; 21(1):326. PubMed ID: 37833769
[TBL] [Abstract][Full Text] [Related]
6. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
7. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
9. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
10. Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study.
Higuchi M; Inomata S; Yamaguchi H; Saito T; Suzuki H
J Cardiothorac Surg; 2023 Jul; 18(1):235. PubMed ID: 37475037
[TBL] [Abstract][Full Text] [Related]
11. Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kwok C; Khorasanchi A; Psutka SP; Hinkley M; Dason S; Sundi D; Yang Y; Yang Y; Verschraegen C; Gross EE; Orcutt D; Yin M
Front Oncol; 2023; 13():1231831. PubMed ID: 37576889
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs.
Chen YY; Yen YT; Lai WW; Huang WL; Chang CC; Tseng YL
Thorac Cancer; 2021 Oct; 12(20):2655-2665. PubMed ID: 34498378
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
14. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
[TBL] [Abstract][Full Text] [Related]
15. Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study.
Zhao D; Xu L; Wu J; She Y; Su H; Hou L; E H; Zhang L; Grossi F; Subramanian MP; Kim AW; Zhu Y; Chen C
Transl Lung Cancer Res; 2022 Jul; 11(7):1468-1478. PubMed ID: 35958337
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K; Yamada T; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Takagi K; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765903
[TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
19. Salvage Surgery for Advanced Lung Adenocarcinoma After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment.
Lin MW; Yu SL; Hsu YC; Chen YM; Lee YH; Hsiao YJ; Lin JW; Su TJ; Jeffrey Yang CF; Chiang XH; Hsu HH; Chen JS; Hsieh MS
Ann Thorac Surg; 2023 Jul; 116(1):111-119. PubMed ID: 36739067
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
Diong NC; Liu CC; Shih CS; Wu MC; Huang CJ; Hung CF
World J Surg Oncol; 2022 Nov; 20(1):370. PubMed ID: 36434641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
